Biognosys at SITC 2020 - Biognosys

Biognosys at SITC 2020

BIOGNOSYS POSTERS

Biognosys is proud to announce the presentation of two posters at the 35th Anniversary

Annual Meeting of the Society for Immunotherapy of Cancer (SITC):

Discovery of Ganglioside GM2 Activator as a Novel Proteomic Biomarker Associated with Response to Treatment in First-line Melanoma Subjects Treated with PD-1 Immunotherapy

K. Beeler1, J. Vowinckel1, M. Soste1, D. Mallardo2, M. Capone2, M. Gabriele2, A. Sorrentino2, V. Vanella2, K. Sklodowski2, D. Heinzmann2, P. Ascierto2
1) Biognosys AG, Schlieren (Zurich), Switzerland 2) Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy

Integrating Deep Proteomic Profiling with Survival Analysis to Identify Novel Biomarkers of Response to PD-1 Blockade in NSCLC Patients

V. Dozio1, S. Lopez-Lastra3, A. Lanzós1, K. Sklodowski1, K. Beeler1, E. Romano2, 3
1) Biognosys AG, Schlieren (Zurich), Switzerland 2) Medical Oncology Department, Institut Curie, Paris, France 3) Center for Cancer Immunotherapy, Institut Curie, Paris, France

VIRTUAL EXHIBITION

The ESMO Virtual Exhibition takes place from Tuesday 10 November to Sunday 15 November 2020. Check out our virtual booth and chat live with our team via the virtual platform.

Visit our booth here (only for SITC registrants).

MORE INFORMATION

 

More information about our offerings for Oncology Research is available

 here

More information about our offerings for Clinical Studies is available

here

More information about our offerings for Pre-clinical Evaluation is available

here

More information about our offerings for Discovery Biology is available

here

SPEAK TO OUR TEAM

 

Book a meeting with our team to get your personal presentation of our posters!

Request a consultation with our proteomics experts to explore how our proteomics platform can accelerate your research!

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact

    Close banner

    New: Drug Target Validation

    Reveal Binding Sites with Structural Proteomics

    New: Drug Target Validation

    Reveal Compound Binding Sites with Structural Proteomics

    Learn More